CytoAgents reaches FDA milestone and closes on $7 million funding round led by PCG Capital

A Pittsburgh-based biotech startup announced it reached the next milestone in its pursuit of full U.S. Food and Drug Administration (FDA) approval for its drug that looks to aid cancer patients undergoing immunotherapy treatment. This new clearance for CytoAgents Inc., which employs four people full-time, comes just days after the startup closed on a $7 million Series A2 equity-based funding round, which Pittsburgh-based PCG Capital led with support from BlueTree Allied Angels and a syndicate of local oncologists. It brings the startup’s total funding to $20 million since its founding in 2018. Read more >>